<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BALSALAZIDE DISODIUM - balsalazide disodiumÂ capsuleÂ </strong><br>AvPAK<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">         These highlights do not include all the information needed to use Balsalazide Disodium Capsules, USP safely and effectively. See full prescribing information for balsalazide.      </span><span class="Bold"><br><br>         Balsalazide Disodium Capsules, USP         <br>Initial U.S. Approval: 2000<br></span>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Drug Interactions (<a href="#ID_4b508b80-34a5-3a7a-59bb-7f0f33152730">7</a>)<a href="#ID_91847904-b544-b9f7-0b5f-389e2ae8fc0a"></a>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  2/2007 </p>
<p class="Highlighta">Postmarketing Experience (<a href="#ID_6c997e51-56cd-949c-ed37-6e8fe23184c8">6.2</a>) <a href="#ID_ef7d4f7d-ad7e-b8f0-6ae6-fc8f423a724e"></a>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â  5/2008 </p>
</div>
</div>
<div><div></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul>
<li>Balsalazide is a locally acting aminosalicylate indicated for the treatment of mildly to moderately active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> in adults (<a href="#ID_b3857263-7c5f-579b-4500-1c210d9359ea">1</a>)</li>
<li>Safety and effectiveness of balsalazide beyond 12 weeks in adults have not been established. (<a href="#ID_b3857263-7c5f-579b-4500-1c210d9359ea">1</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Adult dose is three 750 mg balsalazide disodium capsules 3 times a day (6.75 g/day) with or without food for 8 weeks. Some adult patients required treatment for up to 12 weeks. (<a href="#ID_1161b685-a3c0-bc1d-eac9-078255ce300e">2.1</a>)</li>
<li>Capsules may be swallowed whole or may be opened and sprinkled on applesauce, then chewed or swallowed immediately. (<a href="#ID_91847904-b544-b9f7-0b5f-389e2ae8fc0a">2.2</a>, <a href="#ID_e81072ea-7ff1-53d3-9fe5-e35043bfa5ce">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 750 mg (<a href="#ID_4fe4001c-1572-9466-d125-5acbec67a401">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to salicylates or to any of the components of balsalazide disodium capsules or balsalazide metabolites. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may include, but are not limited to the following: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>. (<a href="#ID_164462ab-d97f-fcc3-c1c1-a422bd8d05a0">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Exacerbation of the symptoms of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> was reported in adult patients. ObserveÂ  patients closely for worsening of these symptoms while on treatment. (<a href="#ID_ef7d4f7d-ad7e-b8f0-6ae6-fc8f423a724e">5.1</a>)</li>
<li>Prolonged gastric retention of balsalazide may occur in patients with <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span>. (<a href="#ID_388c4111-924e-f416-845d-0bd14c43b013">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions in adults (incidence â‰¥3%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>,<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>. Adverse reactions in childrenwere similar. (<a href="#ID_a87c8952-fb82-5bc0-000b-30b1d4062827">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 orFDA at 1-800-FDA-1088 or</span><span class="Bold">www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">In an <span class="Italics">in vitro</span> study using human liver microsomes, balsalazide and its metabolites were notshown to inhibit the major CYP enzymes evaluated (CYP1A2, CYP2C9, CYP2C19, CYP2D6, andCYP3A4/5). (<a href="#ID_4b508b80-34a5-3a7a-59bb-7f0f33152730">7</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Use balsalazide with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. (<a href="#ID_fffc26eb-c020-00de-36d4-0645ed0dad75">5.3</a>) </p>
<p class="Highlighta">Pediatric: Pediatric use information is protected by marketing exclusivity. (<a href="#ID_7ccedae0-9a32-e477-936d-f30a2bd34769">8.4</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 11/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">RECENT MAJOR CHANGES SECTION</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Administration Alternatives</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Exacerbations of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">Pyloric Stenosis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Renal</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal  Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adult Studies</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Important Precautions Regarding Balsalazide Disodium Capsules, USP</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 What Patients Should Know About Adverse Reactions</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 What Patients Should Know About Taking Balsalazide With Other Medication</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_b3857263-7c5f-579b-4500-1c210d9359ea"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Balsalazide disodium capsules, USP are indicated for the treatment of mildly to moderately active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> in adults. Safety and effectiveness of balsalazide beyond 12 weeks in adults have not been established.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_2485299c-3408-dbf8-de1f-dac082e7634d"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1161b685-a3c0-bc1d-eac9-078255ce300e"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Dose</h2>
<p class="First">For treatment of active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> in adult patients, the usual dose is three 750 mg balsalazide disodium capsules to be taken 3 times a day (6.75 g per day) for up to 8 weeks. Some patients in the adult clinical trials required treatment for up to 12 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_91847904-b544-b9f7-0b5f-389e2ae8fc0a"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Administration Alternatives</h2>
<p class="First">Balsalazide disodium capsules may also be administered by carefully opening the capsule and sprinkling the capsule contents on applesauce. The entire drug/applesauce mixture should be swallowed immediately; the contents may be chewed, if necessary, since contents of balsalazide disodium capsules are NOT coated beads/granules. Patients should be instructed not to store any drug/applesauce mixture for future use.</p>
<p>If the capsules are opened for sprinkling, color variation of the powder inside the capsules ranges from orange to yellow and is expected due to color variation of the active pharmaceutical ingredient. </p>
<p>
         Teeth and/or tongue staining may occur in some patients who use balsalazide disodium capsules in sprinkle form with food.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_4fe4001c-1572-9466-d125-5acbec67a401"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Balsalazide is available as opaque white capsules containing 750 mg balsalazide disodium, imprinted with â€œAPO B750â€? in red ink.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_164462ab-d97f-fcc3-c1c1-a422bd8d05a0"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to salicylates or to any of the components of balsalazide disodium capsules or balsalazide metabolites. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may include, but are not limited to the following: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_bc0b33ef-6875-6a81-25cc-724543c35333"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ef7d4f7d-ad7e-b8f0-6ae6-fc8f423a724e"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Exacerbations of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></h2>
<p class="First">In the adult clinical trials, 3 out of 259 patients reported exacerbation of the symptoms of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</p>
<p>Observe patients closely for worsening of these symptoms while on treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_388c4111-924e-f416-845d-0bd14c43b013"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">Pyloric Stenosis</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span> may have prolonged gastric retention of balsalazide disodium capsules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fffc26eb-c020-00de-36d4-0645ed0dad75"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Renal</h2>
<p class="First">Renal toxicity has been observed in animals and patients given other mesalamine products.Therefore, caution should be exercised when administering balsalazide capsules to patients with known renal dysfunction or a history of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. <span class="Italics">[See <a href="#ID_491d08b4-ed61-2094-08dd-34c1e0350087">Nonclinical Toxicology (13.2)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_d5dc58dc-c9e6-0d00-144d-23b0a53490f0"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_a87c8952-fb82-5bc0-000b-30b1d4062827"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Italics">Adult <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></span></p>
<p>During clinical development, 259 adult patients with active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> were exposed to 6.75 g/day balsalazide in 4 controlled trials.</p>
<p>In the 4 controlled clinical trials patients receiving a balsalazide dose of 6.75 g/day most frequently reported the following adverse reactions: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (8%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (6%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (4%), <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span> (4%), and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (4%).Withdrawal from therapy due to adverse reactions was comparable among patients on balsalazide and placebo.</p>
<p>Adverse reactions reported by 1% or more of patients who participated in the four well controlled, Phase 3 trials are presented by treatment groupÂ (Table 1).</p>
<p>The number of placebo patients (35), however, is too small for valid comparisons. Some adverse reactions, such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> were reported more frequently in women than in men. <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> can be part of the clinical presentation of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</p>
<a name="SPLSERV-8948a758-7f76-485a-2411-37c93870e81f"></a><table width="75%">
<caption><span>Table 1: Adverse Reactions Occurring in â‰¥ 1% of Adult Balsalazide Patients in Controlled Trials<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col span="1" width="45.8%">
<col span="1" width="29.8%">
<col span="1" width="24.4%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd> Adverse reactions occurring in at least 1% of Balsalazide Patients which were less frequent than placebo for the same event were not included in the table. </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" colspan="1" rowspan="1" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule" align="center" colspan="1" rowspan="1" valign="top">
<p class="First"><span class="Bold">Balsalazide Capsules 6.75 g/ day</span></p>
<span class="Bold">[N = 259]</span>
</td>
<td class="Botrule" align="center" colspan="1" rowspan="1" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">[N = 35]</span>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">16 (6%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 (3%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" colspan="1" rowspan="1" valign="top">14 (5%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">1 (3%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center" colspan="1" rowspan="1" valign="top">9 (4%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center" colspan="1" rowspan="1" valign="top">6 (2%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">6 (2%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">6 (2%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">5 (2%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">5 (2%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">5 (2%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">4 (2%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">4 (2%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center" colspan="1" rowspan="1" valign="top">4 (2%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">3 (1%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center" colspan="1" rowspan="1" valign="top">3 (1%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Flu-like disorder </td>
<td align="center" colspan="1" rowspan="1" valign="top">3 (1%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">3 (1%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Cramps</span> </td>
<td align="center" colspan="1" rowspan="1" valign="top">3 (1%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" colspan="1" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td class="Botrule" align="center" colspan="1" rowspan="1" valign="top">3 (1%)</td>
<td class="Botrule" align="center" colspan="1" rowspan="1" valign="top">0%</td>
</tr>
</tbody>
</table>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6c997e51-56cd-949c-ed37-6e8fe23184c8"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The following adverse reactions have been identified during post-approval use of balsalazide in clinical practice:</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (with and without <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>), alveolitis, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions have been chosen for inclusion due to a combination of seriousness, frequency of reporting, or potential causal connection to balsalazide.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Hepatic</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Postmarketing adverse reactions of hepatotoxicity have been reported for products which contain (or are metabolized to) mesalamine, including elevated liver function tests (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, cirrhosis, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular damage</span> including <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. Some of these cases were fatal; however, no fatalities associated with these adverse reactions were reported in balsalazide clinical trials. One case of Kawasaki-like syndrome which included hepatic function changes was also reported, however, this adverse reaction was not reported in balsalazide clinical trials.</span></p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_4b508b80-34a5-3a7a-59bb-7f0f33152730"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>In an <span class="Italics">in vitro</span>study using human liver microsomes, balsalazide and its metabolites [5-aminosalicylic acid (5-ASA), N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA), 4-aminobenzoyl-Î²-alanine (4-ABA) and N-acetyl-4-aminobenzoyl-Î²â€“alanine (N-Ac-4-ABA)] were not shown to inhibit the major CYP enzymes evaluated (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5). Therefore, balsalazide and its metabolites are not expected to inhibit the metabolism of other drugs which are substrates of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_a81df35c-1dc8-61d8-07b8-89f6d1b52ba4"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_68b46a25-85a1-ee74-7b3c-c16d4839724d"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. Reproduction studies were performed in rats and rabbits at oral doses up to 2 g/kg/day, 2.4 and 4.7 times the recommended human dose based on body surface area for the rat and rabbit, respectively, and revealed no evidence of impaired fertility or harm to the fetus due to balsalazide disodium. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_70272490-c4d3-fe3a-07df-fd89d2f4bf69"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether balsalazide disodium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when balsalazide is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_7ccedae0-9a32-e477-936d-f30a2bd34769"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Pediatric use information is protected by marketing exclusivity.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_6e23d067-8ab7-0e61-5206-d3f8e56bff5e"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has occurred with balsalazide. A 3-year-old boy is reported to have ingested 2 g of another mesalamine product. He was treated with ipecac and activated charcoal with no adverse reactions.</p>
<p>If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs with balsalazide, treatment should be supportive, with particular attention to correction of electrolyte abnormalities.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_f605983d-c1ea-8dbf-feea-ba11c06af169"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Each balsalazide disodium capsule, USP contains 750 mg of balsalazide disodium, a prodrug that is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid or 5-ASA), an anti-inflammatory drug. Each capsule of balsalazide (750 mg) is equivalent to 267 mg of mesalamine. Balsalazide disodium has the chemical name (E)-5-[[-4-[[(2- carboxyethyl)amino]carbonyl] phenyl]azo]-2-hydroxybenzoic acid, disodium salt, dihydrate. Its structural formula is:</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â  <img alt="structural-formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529&amp;name=structural-formula.jpg"></p>
<p>Molecular Weight: 437.32</p>
<p>Molecular Formula: C<span class="Sub">17</span>H<span class="Sub">13</span>N<span class="Sub">3</span>O<span class="Sub">6</span>Na<span class="Sub">2</span>â€¢2H<span class="Sub">2</span>O</p>
<p>Balsalazide disodium is a stable, odorless orange to yellow microcrystalline powder.It is freely soluble in water and isotonic saline, sparingly soluble in methanol and ethanol, and practically insoluble in all other organic solvents.</p>
<p>Inactive Ingredients: Each hard gelatin capsule contains colloidal silicon dioxide, magnesium stearate and titanium dioxide. The capsule imprinting ink contains propylene glycol, strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> solution, shellac and red iron oxide. The sodium content of each capsule is approximately 86 mg.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_0d4858d9-179c-8b4d-5637-96a2c3c620a2"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_d48a90b3-85d2-bfb7-6b81-344c6b2952c4"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and the 4-aminobenzoyl-Î²-alanine carrier moiety. The carrier moiety released when balsalazide disodium is cleaved is only minimally absorbed and is largely inert.</p>
<p>The mechanism of action of 5-ASA is unknown, but appears to be local to the colonic mucosa rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>, and it is possible that 5-ASA diminishes <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> by blocking production of arachidonic acid metabolites in the colon.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_e81072ea-7ff1-53d3-9fe5-e35043bfa5ce"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Balsalazide disodium capsules contain a powder of balsalazide disodium that is insoluble in acid and designed to be delivered to the colon as the intact prodrug. Upon reaching the colon, bacterial azoreductases cleave the compound to release 5-ASA, the therapeutically active portion of the molecule, and 4-aminobenzoyl-Î²-alanine. The 5-ASA is further metabolized to yield Nacetyl-5-aminosalicylic acid (N-Ac-5-ASA), a second key metabolite.</p>
<p><span class="Italics">Absorption</span></p>
<p>The plasma pharmacokinetics of balsalazide and its key metabolites from a crossover study in healthy volunteers are summarized in Table 2. In this study, a single oral dose of balsalazide 2.25 g was administered to healthy volunteers as intact capsules (3 x 750 mg) under fasting conditions, as intact capsules (3 x 750 mg) after a high-fat meal, and unencapsulated (3 x 750 mg) as sprinkles on applesauce.</p>
<a name="SPLSERV-0cd3e240-9809-80b8-9fc7-933c553ab345"></a><table width="873">
<caption><span>Â Table 2: Plasma Pharmacokinetics for Balsalazide and Key Metabolites (5-ASA and N-Ac-5-ASA) with Administration of Balsalazide Following a Fast, a High-Fat Meal, and Drug Contents Sprinkled on Applesauce (Mean Â± SD)</span></caption>
<col span="1" width="25.8%">
<col span="1" width="25.2%">
<col span="1" width="24.5%">
<col span="1" width="24.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" colspan="1" rowspan="1" valign="top"></td>
<td class="Botrule" align="center" colspan="1" rowspan="1" valign="top">
<p class="First"><span class="Bold">Fasting</span></p>
<span class="Bold">n = 17</span>
</td>
<td class="Botrule" align="center" colspan="1" rowspan="1" valign="top">
<p class="First"><span class="Bold">High-Fat Meal</span></p>
<span class="Bold">n = 17</span>
</td>
<td class="Botrule" align="center" colspan="1" rowspan="1" valign="top">
<p class="First"><span class="Bold">Sprinkled</span></p>
<span class="Bold">n = 17</span>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">C<span class="Sub">max </span>(mcg/mL)</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â  Balsalazide</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.51 Â± 0.32</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.45 Â± 0.39</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.21 Â± 0.12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â  5-ASA</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.22 Â± 0.12</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.11 Â± 0.136</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.29 Â± 0.17</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â  N-Ac-5-ASA</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.88 Â± 0.39</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.64 Â± 0.534</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.04 Â± 0.57</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AUC<span class="Sub">last </span>mcgÂ·hr/mL)</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â  Balsalazide</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.35 Â± 0.73</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.52 Â± 1.01</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.87 Â± 0.48</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â  5-ASA</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.59 Â± 1.46</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.10 Â± 2.58</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.99 Â± 1.70</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â  N-Ac-5-ASA</td>
<td align="center" colspan="1" rowspan="1" valign="top">17.8 Â± 8.14</td>
<td align="center" colspan="1" rowspan="1" valign="top">17.7 Â± 13.7</td>
<td align="center" colspan="1" rowspan="1" valign="top">20.0 Â± 11.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">T<span class="Sub">max </span>(h)</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â  Balsalazide</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.8 Â± 0.85</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.2 Â± 1.11</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.6 Â± 0.44</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â  5-ASA</td>
<td align="center" colspan="1" rowspan="1" valign="top">8.2 Â± 1.98</td>
<td align="center" colspan="1" rowspan="1" valign="top">22.0 Â± 8.23</td>
<td align="center" colspan="1" rowspan="1" valign="top">8.7 Â± 1.99</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" colspan="1" rowspan="1" valign="top">Â Â  N-Ac-5-ASA</td>
<td class="Botrule" align="center" colspan="1" rowspan="1" valign="top">9.9 Â± 2.49</td>
<td class="Botrule" align="center" colspan="1" rowspan="1" valign="top">20.2 Â± 8.94</td>
<td class="Botrule" align="center" colspan="1" rowspan="1" valign="top">10.8 Â± 5.39</td>
</tr>
</tbody>
</table>
<p>A relatively low systemic exposure was observed under all three administered conditions (fasting, fed with high-fat meal, sprinkled on applesauce), which reflects the variable, but minimal absorption of balsalazide disodium and its metabolites. The data indicate that both C<span class="Sub">max</span> and AUC<span class="Sub">last</span> were lower, while tmax was markedly prolonged, under fed (high-fat meal) compared to fasted conditions. Moreover, the data suggest that dosing balsalazide disodium as a sprinkle or as a capsule provides highly variable, but relatively similar mean pharmacokinetic parameter values. No inference can be made as to how the systemic exposure differences of balsalazide and its metabolites in this study might predict the clinical efficacy under different dosing conditions (i.e., fasted, fed with high-fat meal, or sprinkled on applesauce) since clinical efficacy after balsalazide disodium administration is presumed to be primarily due to the local effects of 5- ASA on the colonic mucosa.</p>
<p>In a separate study of adult patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, who received balsalazide, 1.5 g twice daily, for over 1 year, systemic drug exposure, based on mean AUC values, was up to 60 times greater (0.008 mcgâ€¢hr/mL to 0.480 mcgâ€¢hr/mL) when compared to that obtained in healthy subjects who received the same dose.</p>
<p><span class="Italics">Distribution</span></p>
<p>The binding of balsalazide to human plasma proteins was â‰¥99%.</p>
<p><span class="Italics">Metabolism</span></p>
<p>The products of the azoreduction of this compound, 5-ASA and 4-aminobenzoyl-Î²-alanine, and their N-acetylated metabolites have been identified in plasma, urine and feces.</p>
<p><span class="Italics">Elimination</span></p>
<p>Following single-dose administration of 2.25 g balsalazide (three 750 mg capsules) under fasting conditions in healthy subjects, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.20%, 0.22% and 10.2%, respectively.</p>
<p>In a multiple-dose study in healthy subjects receiving a balsalazide dose of two 750 mg capsules twice daily (3 g/day) for 10 days, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.1%, 0%, and 11.3%, respectively. During this study, subjects received their morning dose0.5 hours after being fed a standard meal, and subjects received their evening dose 2 hours after being fed a standard meal.</p>
<p>In a study with 10 healthy volunteers, 65% of a single 2.25-gram dose of balsalazide was recovered as 5-ASA, 4-aminobenzoyl-Î²-alanine, and the N-acetylated metabolites in feces, while &lt;1% of the dose was recovered as parent compound.</p>
<p>In a study that examined the disposition of balsalazide in patients who were taking 3 to 6 g of balsalazide daily for more than 1 year and who were in remission from <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, less than1% of an oral dose was recovered as intact balsalazide in the urine. Less than 4% of the dose was recovered as 5-ASA, while virtually no 4-aminobenzoyl-Î²-alanine was detected in urine. The mean urinary recovery of N-Ac-5-ASA and N-acetyl-4-aminobenzoyl-Î²-alanine comprised &lt;16% and &lt;12% of the balsalazide dose, respectively. No fecal recovery studies were performed in this population.</p>
<p>All pharmacokinetic studies with balsalazide are characterized by large variability in the plasma concentration versus time profiles for balsalazide and its metabolites, thus half-life estimates of these analytes are indeterminate.</p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_d8e8beba-0a15-4261-f1e4-12786633eceb"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_68f96098-05ac-9b93-8426-395a5f5d81b7"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 24-month rat (Sprague Dawley) carcinogenicity study, oral (dietary) balsalazide disodium at doses up to 2 g/kg/day was not tumorigenic. For a 50-kg person of average height this dose represents 2.4 times the recommended human dose on a body surface area basis. Balsalazide disodium was not genotoxic in the following in vitro or <span class="Italics">in vivo</span> tests: Ames test, human lymphocyte chromosomal aberration test, and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (L5178Y/TK+/-) forward mutation test, or mouse micronucleus test. However, it was genotoxic in the in vitro Chinese hamster lung cell (CH V79/HGPRT) forward mutation test.</p>
<p>4-aminobenzoyl-Î²-alanine, a metabolite of balsalazide disodium, was not genotoxic in the Ames test and the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (L5178Y/TK+/-) forward mutation test but was positive in the human lymphocyte chromosomal aberration test. N-acetyl-4-aminobenzoyl-Î²-alanine, a conjugated metabolite of balsalazide disodium, was not genotoxic in Ames test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (L5178Y/TK+/-) forward mutation test, or the human lymphocyte chromosomal aberration test. Balsalazide disodium at oral doses up to 2 g/kg/day, 2.4 times the recommended human dose based on body surface area, was found to have no effect on fertility and reproductive performance in rats.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_491d08b4-ed61-2094-08dd-34c1e0350087"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal  Toxicology</h2>
<p class="First"><span class="Italics">Renal Toxicity</span></p>
<p>In animal studies conducted at doses up to 2000 mg/kg (approximately 21 times the recommended 6.75 g/day dose on a mg/kg basis for a 70 kg person), balsalazide demonstrated no nephrotoxic effects in rats or dogs.</p>
<p><span class="Italics">Overdosage</span></p>
<p>A single oral dose of balsalazide disodium at 5 g/kg or 4-aminobenzoyl-Î²-alanine, a metabolite of balsalazide disodium, at 1 g/kg was non-lethal in mice and rats. No symptoms of acute toxicity were seen at these doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_283bb466-a43d-438c-5aa8-da2410254ec8"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cf246a6c-b329-a785-4cd2-32e6c3e0def3"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adult Studies</h2>
<p class="First">Two randomized, double-blind studies were conducted in adults. In the first trial, 103 patients with active mild-to-moderate <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> with sigmoidoscopy findings of friable or spontaneously <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> mucosa were randomized and treated with balsalazide 6.75 g/day or balsalazide 2.25 g/day. The primary efficacy endpoint was reduction of <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> and improvement of at least one of the other assessed symptoms (stool frequency, patient functional assessment, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, sigmoidoscopic grade, and physicianâ€™s global assessment [PGA]). Outcome assessment for <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> at each interim period (week 2, 4, and 8) encompassed a 4-day period (96 hours).Â  Results demonstrated a statistically significant difference between high and low doses of balsalazide (Figure 1).</p>
<p><span class="Bold">Figure 1: Percentage of Patients Improved at 8 weeks</span></p>
<p><img alt="Figure-1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529&amp;name=Figure-1.jpg"></p>
<p>A second study, conducted in Europe, confirmed findings of symptomatic improvement.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_9886d0ef-d5e4-bdd9-0980-3a50a20b0484"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Balsalazide Disodium Capsules, USP are available as white, opaque capsules imprinted â€œAPO B750â€? in red ink.</p>
<p>Balsalazide Disodium Capsules, USP are supplied as follows:</p>
<p>NDCÂ  50268-102-13Â Â  10 capsules per car, 3 cards per carton</p>
<p>Dispensed in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Punch Material. For Institutional Use Only.</p>
<p><span class="Bold">Storage</span></p>
<p>Store at 20Âº to 25ÂºC (68Âº to 77ÂºF); excursions permitted between 15Âº and 30ÂºC (59Âº and 86ÂºF).</p>
<p>See USP Controlled Room Temperature.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_a557ee37-5122-dc08-82ee-3a732a247006"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_aae52043-4feb-2595-0d10-043bc513e6c3"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Important Precautions Regarding Balsalazide Disodium Capsules, USP</h2>
<p class="First"></p>
<ul>
<li>Instruct patients not to take balsalazide if they have a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to salicylates (e.g., aspirin).</li>
<li>Patients should be instructed to contact their health care provider under the following circumstances:<p class="First">- If they experience a worsening of their <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> symptoms.</p>
<p>- If they are diagnosed with <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span>, because balsalazide disodium capsules may be slow to pass through their digestive tract.</p>
<p>- If they are diagnosed with renal dysfunction. Damage to the kidney has been observed in people given medications similar to balsalazide.</p>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5829731e-047e-b7d8-ed6b-ecd37e8ef373"></a><a name="section-15.2"></a><p></p>
<h2>17.2 What Patients Should Know About Adverse Reactions</h2>
<p class="First"></p>
<ul>
<li>In adult clinical trials the most common adverse reactions were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>,Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>.</li>
<li>Inform patients that this listing of adverse reactions is not complete and not all adverseÂ reactions can be anticipated. If appropriate, a more comprehensive list of adverse reactionsÂ can be discussed with patients.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4fa7078e-4bb9-0613-93f8-e074094282bb"></a><a name="section-15.3"></a><p></p>
<h2>17.3 What Patients Should Know About Taking Balsalazide With Other Medication</h2>
<ul><li style="border-left:1px solid;">
<span class="XmChange"></span>Based upon limited studies conducted in a test tube, balsalazide is not believed to interfere with other drugs by preventing how the liver functions. However, as the studies were limited in scope, you should always consult your doctor and discuss potential interactions prior to initiating any new drug.</li></ul>
<p class="First"><span class="Bold">BALSALAZIDE DISODIUM CAPSULES, USP 750 mg</span></p>
<table frame="void" width="45%"><tbody class="Headless">
<tr class="First Toprule">
<td colspan="1" rowspan="1">Manufactured for:</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">AvKARE, Inc.</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pulaski, TN 38478</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr class="Last">
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
</tbody></table>
<p>Mfg. Rev. 5 02/14</p>
<p>AV Rev. 11/14 (P)<br>AvPAK<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_2533575f-cc40-be6e-b0b8-068878312d5f"></a><a name="section-16"></a><p></p>
<h1> PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC</span> 50268-102-13 <br><span class="Bold">Balsalazide Disodium Capsules, USP<br></span>750 mg<br>Rx Only<br>30 Capsules (3 X 10) Unit Dose<br><br>5026810213<br><br><span class="Bold">NDC</span> 50268-102-13 <br><span class="Bold">Balsalazide Disodium Capsules, USP<br></span>750 mg<br>Rx Only<br>30 Capsules (3 X 10) Unit Dose<br><br>5026810213<br>Â </p>
<p><span class="Bold">Each capsule contains</span> 750 mg of balsalazide disodium.<br><br><span class="Bold">Usual Dosage</span>: See package insert.<br><br><span class="Bold">Store</span> at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature].  </p>
<p><span class="Bold">Dispense</span> in a tight, light-resistant container [see USP].<br><br><span class="Bold">Keep this and all medications out of the reach of children.</span></p>
<p>Manufactured for:<br><span class="Bold">AvKARE, Inc.</span><br>Pulaski, TN 38478  </p>
<p><span class="Bold">AvPAK<br></span><span class="Italics">A PRODUCT OF </span>AvKARE<br><br>Mfg. Rev. 330318Â Â Â Â Â Â Â  AV 11/14 (P)<br><span class="Italics"></span></p>
<div class="Figure"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529&amp;name=Screen%20Shot%202014-11-06%20at%2010.11.43%20AM.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BALSALAZIDE DISODIUM Â 		
					</strong><br><span class="contentTableReg">balsalazide disodium capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50268-102(NDC:60505-2575)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BALSALAZIDE DISODIUM</strong> (BALSALAZIDE) </td>
<td class="formItem">BALSALAZIDE DISODIUM</td>
<td class="formItem">750Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;B750</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50268-102-13</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50268-102-11</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077883</td>
<td class="formItem">11/06/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>AvPAK
							(832926666)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>98ab4c37-72f9-61d0-25b9-cb41c956c9e1</div>
<div>Set id: 509b83b6-cde6-393b-8560-557793b6a529</div>
<div>Version: 1</div>
<div>Effective Time: 20141106</div>
</div>
</div>Â <div class="DistributorName">AvPAK</div></p>
</body></html>
